Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123>>>
64 Items
Title  Creator  Group name  Publishing year 
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas Becker et al. EquipeCTCS 2025-01-06
Robotic posterior pelvic exenteration for locally advanced rectal cancer-A video vignette Colombo et al. EquipeCTCS 2024-10
Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer Colombo et al. EquipeCTCS 2024-10
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery Houvenaeghel et al. EquipeCTCS 2024-09-27
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment Bruciamacchie et al. EquipeCG 2024-11-29
Port placement strategies and management of the robotic system during total colectomy or total coloproctectomy for cancer - A video vignette Bourla et al. EquipeCTCS 2023-08
Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? Quesada et al. EquipeCTCS 2023-07-10
Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery Houvenaeghel et al. EquipeCTCS 2023-09-14
Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse Brouillard-Saby et al. EquipeCTCS 2023-04-03
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer Vendrell et al. EquipeCTCS 2023-09-16
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib Velazquez et al. EquipeMY 2023
[Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?] Thomas et al. EquipePC 2022-02
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network Romeo et al. EquipeCTCS 2022-01-12
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases Giguelay et al. EquipePM 2022
Tailored Management with Highly-Selective Diversion for Low Colorectal Anastomosis: Biochemical Postoperative Follow-Up and Long-Term Results from a Single-Institution Cohort Rouanet et al. EquipeCTCS 2022-04
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study Michalet et al. EquipeMY 2022
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2022-12-20
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort Thomas et al. EquipeCTCS 2022-10
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy Neron et al. EquipeAT 2022-04-19
In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2 du Manoir et al. EquipeCTCS 2022-07
Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade Ovarian Serous Carcinoma Ruano et al. EquipeCTCS 2022-11-24
Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing Escherichia coli in patients with mid or low rectal cancer: a prospective clinical study protocol (MICARE) Taoum et al. EquipeCTCS 2022-12-02
Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study Houvenaeghel et al. EquipeCTCS 2022-11
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial Houvenaeghel et al. EquipeCTCS 2021-10-08
Robotic right colectomy with complete mesocolic excision, D3 lymphadenectomy and intracorporeal anastomosis for a caecal adenocarcinoma - A Video Vignette Castaldi et al. EquipeCTCS 2021-06
123>>>
64 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés